Skip to main
PYXS

Pyxis Oncology (PYXS) Stock Forecast & Price Target

Pyxis Oncology (PYXS) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pyxis Oncology has demonstrated a strengthened outlook for its product candidate, micvotabart pelidotin (MICVO), particularly in the 2L+ head and neck squamous cell carcinoma (HNSCC) setting, where consistent activity indicates competitive positioning. Notably, the improvements in tolerability observed with a lower micvodose enhance its potential for increased patient enrollment, with an adjusted estimate forecasting a U.S. patient population of 29,000 for this treatment line. As safety results suggest an optimal dosing strategy that could allow for effective combination treatment in earlier lines, the positive efficacy trends forecast a broader market opportunity for MICVO, bolstering investor confidence in the company’s future growth potential.

Bears say

Pyxis Oncology Inc faces significant downside risks due to potential unacceptable toxicity or safety issues related to its investigational product candidate micvotabart pelidotin (MICVO), which could lead to share prices trading down to cash levels in the next 12 months, estimated at approximately $1.00. The company's current challenges include disappointing patient enrollment numbers and a notable discontinuation rate in clinical trials, contributing to a decline in share value despite competitive overall response rate (ORR) and disease control rate (DCR) results. Additionally, concerns over the early-stage nature of MICVO, coupled with the highly competitive oncology landscape, heighten the risk of insufficient efficacy and tolerability, which could hinder further development and negatively impact investor sentiment.

Pyxis Oncology (PYXS) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pyxis Oncology and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pyxis Oncology (PYXS) Forecast

Analysts have given Pyxis Oncology (PYXS) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Pyxis Oncology (PYXS) has a Strong Buy consensus rating as of Apr 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pyxis Oncology (PYXS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.